News from biotrends research group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 30, 2013, 11:00 ET

Gastroenterologists Unlikely To Use Celltrion/Hospira's Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority...

Sep 25, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according...

Sep 24, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed...

Sep 19, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Enbrel and Humira Remain the Mainstay for First-Line Biologic Rheumatoid Arthritis Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...

Sep 16, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one...

Sep 09, 2013, 11:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in...

Aug 29, 2013, 09:00 ET

Concerns Over Drug-Resistance Continues To Dominate Medical Practice in Hospital-Treated Gram-Negative Infections

 BioTrends Research Group and Arlington Medical Resources find in their TreatmentTrends®: Gram Negative Infections (US) 2013 report that...

Aug 28, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Tecfidera's Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that patient...

Aug 28, 2013, 08:00 ET

Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds a significant...

Aug 15, 2013, 08:00 ET

Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentech's Lucentis

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed...

Aug 13, 2013, 11:00 ET

From One Month To One Year Post-launch, The User-base Of Roche/Genentech/Chugai's Perjeta Has More Than Doubled

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one year...

Aug 08, 2013, 09:00 ET

Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)

 BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...

Aug 06, 2013, 09:00 ET
Jul 25, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed Physicians Indicate Market Opportunities Exist for Novel MRSA Agents that Provide Improvements in Safety, Dosing and Availability in Oral Formulation

 BioTrends Research Group and Arlington Medical Resources find in their TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US)...

Jul 25, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At Six Months Post-Launch, the User-Base of Pfizer's Xeljanz for Rheumatoid Arthritis Has Nearly Doubled Since Three Months Post-Launch

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at six...

Jul 22, 2013, 08:00 ET

Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that U.S....

Jul 11, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At One Month Post-Launch, Over Half of Surveyed U.S. Neurologists Have Prescribed Biogen Idec's Tecfidera, the Third-to-Market Oral Therapy, to Their Multiple Sclerosis Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

Jul 10, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

After 18 Months On the U.S. Market, Regeneron's Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...

Jul 08, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Over 45 Percent of Surveyed Nephrologists Are Highly Interested in Late-Stage Chronic Kidney Disease Products from OPKO Health, Fibrogen/Astellas, Keryx and Akebia, After Reviewing Brief Product Profiles

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among...